Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Profound Medical Corp T.PRN

Alternate Symbol(s):  PROF

Healthcare Medical Devices
Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum. TULSA-PRO has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer and the transition zone in large volume benign prostatic hyperplasia. It is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.


TSX:PRN - Post by User

Profound Medical Corp > Target 25 installations by YE, up from 14 as of Q2 Conf Call
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Oct 02, 2021 9:03pm
118 Views
Post# 33958086

RE:Target 25 installations by YE, up from 14 as of Q2 Conf Call

RE:Target 25 installations by YE, up from 14 as of Q2 Conf Call
HomerAndCompany wrote:
This increase in the rate of installations is to be facilitated by doubling the size of sales and installation teams by Q4. .


Not sure I understand the numbers ...
- 11 Procedure Centers in USA (one of them doubles as a learning center)
- 1 additional learning center
- 7 in Europe
- 1 in Japan
That's 20 in total

Are they going to 25 in total (5 more)   - OR -   25 in the USA for 2021 ?

Not much time in 2021 if they plan on getting to 25 in the USA alone - unless they're adding but not updating the company map at this time.



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities